{"id":"ono-1101","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ONO-1101 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing the immune response against cancer cells.","oneSentence":"ONO-1101 is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:21.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT06793670","phase":"PHASE4","title":"Landiolol in Mitral Valve Surgery","status":"RECRUITING","sponsor":"Università Vita-Salute San Raffaele","startDate":"2025-01-28","conditions":"Cardiac Failure, Low Cardiac Output Syndrome","enrollment":1500},{"nctId":"NCT07293832","phase":"","title":"Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2024-11-13","conditions":"STEMI","enrollment":100},{"nctId":"NCT07168421","phase":"PHASE4","title":"LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-10","conditions":"Perioperative Myocardial Injury, Autonomic Dysfunction, Cardiovascular (CV) Risk","enrollment":114},{"nctId":"NCT04748796","phase":"PHASE3","title":"Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-02-01","conditions":"Septic Shock, Tachycardia, Mortality During Septic Shock","enrollment":360},{"nctId":"NCT03779178","phase":"PHASE3","title":"Landiolol in Postoperative Atrial Fibrillation","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-01-17","conditions":"Atrial Fibrillation","enrollment":58},{"nctId":"NCT04931225","phase":"PHASE3","title":"LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-07-18","conditions":"Septic Shock","enrollment":44},{"nctId":"NCT04607122","phase":"PHASE3","title":"Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery","status":"COMPLETED","sponsor":"CMC Ambroise Paré","startDate":"2021-01-27","conditions":"Atrial Fibrillation, Cardiac Surgery","enrollment":400},{"nctId":"NCT05554978","phase":"PHASE1, PHASE2","title":"Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-03-03","conditions":"Cardiac Arrest","enrollment":32},{"nctId":"NCT05084118","phase":"PHASE3","title":"Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-10-21","conditions":"Atrial Fibrillation, Postoperative Complications","enrollment":164},{"nctId":"NCT04694092","phase":"NA","title":"Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation","status":"UNKNOWN","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2020-11-05","conditions":"Atrial Fibrillation, Atrial Fibrillation Rapid, Acute Heart Failure","enrollment":40},{"nctId":"NCT04223739","phase":"PHASE4","title":"Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac Surgery","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Cardiac Surgery","enrollment":380},{"nctId":"NCT01741519","phase":"PHASE1","title":"Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2012-12","conditions":"Healthy","enrollment":14},{"nctId":"NCT00212680","phase":"PHASE2","title":"Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan","status":"COMPLETED","sponsor":"Ono Pharma USA Inc","startDate":"1996-12","conditions":"Postoperative Supraventricular Tachyarrythmia","enrollment":100},{"nctId":"NCT00212654","phase":"PHASE2, PHASE3","title":"Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2001-06","conditions":"Postoperative Supraventricular Tachyarrythmia","enrollment":165},{"nctId":"NCT00311038","phase":"PHASE2","title":"Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2006-04","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT00560209","phase":"PHASE2","title":"Study of ONO-1101 in Patients Scheduled for Coronary Angiography","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2007-11","conditions":"Coronary Artery Disease","enrollment":183},{"nctId":"NCT00924586","phase":"PHASE3","title":"Study of ONO-1101 in Patients Scheduled for Multi-Slice Computed Tomography (CT)","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2009-06","conditions":"Coronary Artery Disease","enrollment":258}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ONO-1101","genericName":"ONO-1101","companyName":"Ono Pharmaceutical Co. Ltd","companyId":"ono-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ONO-1101 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}